Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 257

1.

The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease.

Fabiani C, Vitale A, Rigante D, Emmi G, Lopalco G, Di Scala G, Sota J, Orlando I, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L.

Ocul Immunol Inflamm. 2018 Aug 27:1-7. doi: 10.1080/09273948.2018.1511810. [Epub ahead of print]

PMID:
30148652
2.

Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: potential cardiovascular protective role of IL-6 inhibition.

Fioravanti A, Tenti S, Bacarelli MR, Damiani A, Li Gobbi F, Bandinelli F, Cheleschi S, Galeazzi M, Benucci M.

Clin Exp Rheumatol. 2018 Aug 27. [Epub ahead of print]

PMID:
30148441
3.

Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers.

Gentileschi S, Vitale A, Rigante D, Lopalco G, Emmi G, Orlando I, Di Scala G, Sota J, Fabiani C, Frediani B, Galeazzi M, Lapadula G, Iannone F, Cantarini L.

Isr Med Assoc J. 2018 Jul;20(7):438-441.

4.

Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.

Fabiani C, Vitale A, Rigante D, Emmi G, Bitossi A, Lopalco G, Sota J, Guerriero S, Orlando I, Gentileschi S, Iannone F, Frediani B, Galeazzi M, Vannozzi L, Tosi GM, Cantarini L.

Clin Rheumatol. 2018 Aug 11. doi: 10.1007/s10067-018-4228-6. [Epub ahead of print]

PMID:
30099655
5.

Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet's Disease.

Sota J, Vitale A, Rigante D, Orlando I, Lucherini OM, Simpatico A, Lopalco G, Franceschini R, Galeazzi M, Frediani B, Fabiani C, Tosi GM, Cantarini L.

Isr Med Assoc J. 2018 Aug;20(8):517-521.

6.

Intravenous Immunoglobulins as a new opportunity to treat discoid lupus erythematosus: A case report and review of the literature.

Tenti S, Fabbroni M, Mancini V, Russo F, Galeazzi M, Fioravanti A.

Autoimmun Rev. 2018 Aug;17(8):791-795. doi: 10.1016/j.autrev.2018.02.010. Epub 2018 Jun 6. Review.

PMID:
29885539
7.

Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study.

Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, Manna R, Cimaz R, Priori R, Talarico R, de Marchi G, Frassi M, Gallizzi R, Soriano A, Alessio M, Cammelli D, Maggio MC, Gentileschi S, Marcolongo R, La Torre F, Fabiani C, Colafrancesco S, Ricci F, Galozzi P, Viapiana O, Verrecchia E, Pardeo M, Cerrito L, Cavallaro E, Olivieri AN, Paolazzi G, Vitiello G, Maier A, Silvestri E, Stagnaro C, Valesini G, Mosca M, de Vita S, Tincani A, Lapadula G, Frediani B, De Benedetti F, Iannone F, Punzi L, Salvarani C, Galeazzi M, Angotti R, Messina M, Tosi GM, Rigante D, Cantarini L; “Working Group” of Systemic Autoinflammatory Diseases of SIR (Italian Society of Rheumatology).

Clin Rheumatol. 2018 May 17. doi: 10.1007/s10067-018-4119-x. [Epub ahead of print]

PMID:
29770930
8.

Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies.

Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Bitossi A, Orlando I, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L.

Clin Rheumatol. 2018 May 15. doi: 10.1007/s10067-018-4133-z. [Epub ahead of print]

PMID:
29766375
9.

Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab.

Fabiani C, Vitale A, Rigante D, Emmi G, Lopalco G, Sota J, Vannozzi L, di Scala G, Guerriero S, Orlando I, Franceschini R, Capozzoli M, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L.

Clin Rheumatol. 2018 Jun;37(6):1715-1720. doi: 10.1007/s10067-018-4092-4. Epub 2018 Apr 18.

PMID:
29671190
10.

Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis.

Fabiani C, Vitale A, Emmi G, Bitossi A, Lopalco G, Sota J, Guerriero S, Orlando I, Capozzoli M, Fusco F, Rana F, Iannone F, Frediani B, Galeazzi M, Vannozzi L, Tosi GM, Cantarini L.

Clin Rheumatol. 2018 Apr 3. doi: 10.1007/s10067-018-4069-3. [Epub ahead of print]

PMID:
29611087
11.

Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective.

Galeazzi M, Alten R, Chartier M, Elbez Y, Fusaro E, Le Bars M, Lorenz HM, Pagano Mariano G, Muratore M, Nüßlein HG, Patanè G.

Clin Exp Rheumatol. 2018 Mar 21. [Epub ahead of print] No abstract available.

PMID:
29600933
12.

Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease.

Rizzello F, Olivieri I, Armuzzi A, Ayala F, Bettoli V, Bianchi L, Cimino L, Costanzo A, Cristaudo A, D'Angelo S, Daperno M, Fostini AC, Galeazzi M, Gilio M, Gionchetti P, Gisondi P, Lubrano E, Marchesoni A, Offidani A, Orlando A, Pugliese D, Salvarani C, Scarpa R, Vecchi M, Girolomoni G.

Adv Ther. 2018 Apr;35(4):545-562. doi: 10.1007/s12325-018-0672-6. Epub 2018 Mar 7.

13.

Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.

Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, Nüßlein HG, Chartier M, Elbez Y, Rauch C, Le Bars M.

RMD Open. 2017 Dec 29;3(2):e000538. doi: 10.1136/rmdopen-2017-000538. eCollection 2017.

14.

Trapped crystals in synovial fluid: neutrophil extracellular traps from bench to bedside.

Garcia-Gonzalez E, Lucherini OM, Gamberucci A, Alì A, Simpatico A, Lorenzini S, Galeazzi M, Selvi E.

Rheumatology (Oxford). 2018 Apr 1;57(4):759-760. doi: 10.1093/rheumatology/kex502. No abstract available.

PMID:
29385560
15.

Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative.

Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr, Brézin AP, Chee SP, Davis JL, Ramanan AV, Sonoda KH, Carreño E, Nascimento H, Salah S, Salek S, Siak J, Steeples L; Fundamentals of Care for Uveitis International Consensus Group.

Ophthalmology. 2018 May;125(5):757-773. doi: 10.1016/j.ophtha.2017.11.017. Epub 2018 Jan 6. Review.

16.

Could Oxidative Stress Regulate the Expression of MicroRNA-146a and MicroRNA-34a in Human Osteoarthritic Chondrocyte Cultures?

Cheleschi S, De Palma A, Pascarelli NA, Giordano N, Galeazzi M, Tenti S, Fioravanti A.

Int J Mol Sci. 2017 Dec 8;18(12). pii: E2660. doi: 10.3390/ijms18122660.

17.

Hydrostatic pressure as epigenetic modulator in chondrocyte cultures: A study on miRNA-155, miRNA-181a and miRNA-223 expression levels.

De Palma A, Cheleschi S, Pascarelli NA, Giannotti S, Galeazzi M, Fioravanti A.

J Biomech. 2018 Jan 3;66:165-169. doi: 10.1016/j.jbiomech.2017.10.044. Epub 2017 Nov 7.

PMID:
29150345
18.

Can hybrid hyaluronic acid represent a valid approach to treat rizoarthrosis? A retrospective comparative study.

Tenti S, Pascarelli NA, Giannotti S, Galeazzi M, Giordano N, Fioravanti A.

BMC Musculoskelet Disord. 2017 Nov 13;18(1):444. doi: 10.1186/s12891-017-1809-5.

19.

Transitioning from first- to second-generation biosimilars: An appraisal of regulatory and post-marketing challenges.

Blandizzi C, Galeazzi M, Valesini G.

Pharmacol Res. 2018 Feb;128:306-314. doi: 10.1016/j.phrs.2017.10.015. Epub 2017 Nov 3. Review.

20.

Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.

Fabiani C, Sota J, Vitale A, Emmi G, Vannozzi L, Bacherini D, Lopalco G, Guerriero S, Venerito V, Orlando I, Franceschini R, Fusco F, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L.

Ocul Immunol Inflamm. 2017 Nov 3:1-6. doi: 10.1080/09273948.2017.1391297. [Epub ahead of print]

PMID:
29099660

Supplemental Content

Loading ...
Support Center